Status:
COMPLETED
Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients
Lead Sponsor:
Istituto Clinico Humanitas
Conditions:
MALIGNANT PLEURAL MESOTHELIOMA
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the present study is to investigate the molecular predictors of pemetrexed and carboplatin response in tumor samples of a series of MPM patients extracting the DNA and genotyping for the TS...
Detailed Description
Malignant pleural mesothelioma (MPM) is an aggressive tumor that usually has a poor prognosis. The combination of cisplatin and pemetrexed has recently become the standard of care in the first-line tr...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- MPM diagnosis
- Availability of tumor tissue to perform analysis
- Exclusion Criteria :
- Other primary diagnosis
- No archival tissue available
Exclusion
Key Trial Info
Start Date :
January 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT00867711
Start Date
January 1 2009
End Date
December 1 2011
Last Update
December 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Istituto Clinico Humanitas
Rozzano, Milano, Italy, 20089